Precision AQ, a life sciences company focused on expanding patient access to life-changing therapies, has appointed Dan Cummings as its first Chief Commercial Officer.

In this role, Cummings will be responsible for Precision AQ’s commercial and go-to-market strategies, with the goal of bringing Precision AQ’s suite of capabilities to help biopharmaceutical companies advance life-changing therapies to market.

“We are delighted to welcome Dan as Precision AQ’s first Chief Commercial Officer,” said Chad Clark, President and COO of Precision Medicine Group. “Dan brings a unique combination of skills that are highly relevant to our business, including an incredible track record of leading business development and sales operations for start-up and established life sciences companies, as well as experience in market access consulting. He is well-positioned to shape our commercial strategy as we continue synchronizing our evidence and access solutions and pursue our foundational mission of ensuring biopharmaceutical companies succeed in delivering transformative medicines to patients.”

Experience

Cummings brings over a decade of strategy, planning, business development, growth marketing, and sales operations leadership experience to Precision AQ. Most recently, he served as Senior Vice President, Head of Commercial Strategy and Operations at Envision Pharma Group, where he focused on driving growth and oversaw efforts across business development, go-to-market strategy, inside sales, and sales operations. Previously, he was Head of Commercial Operations and Sales at Capsule Pharmacy and, earlier, he held go-to-market-related roles of increasing global responsibility at Syneos Health.

He started his career as a market access consultant at The Dedham Group and Decision Resources Group.

“I am thrilled to join Precision AQ and am eager to bring a customer-first mindset to fully leverage Precision AQ’s connected offerings,” said Cummings. “As we continue to build on our legacy of successfully supporting the commercialization and launch of hundreds of transformative medicines, I am committed to ensuring that Precision AQ is easy to work with and easy to work for.”